Publications by authors named "Matthew Matasar"

Claim this Profile
E
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Matthew Matasar

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL.
Jon E Arnason, Matthew Matasar, Stefano Luminari, David Tucker, Dylan Sun

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Matthew Matasar

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.
Raphael Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, Swetha Kambhampati Thiruvengadam, Matthew Matasar

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.
Zachary D Epstein-Peterson, Anath C Lionel, Ashlee Joseph, Esther Drill, Suheil Albert Atallah-Yunes, Matthew J Matasar

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium.
John Seng Wang, Brandon Lee Ellsworth, Megan Melody, Narendranath Epperla, Deborah M Stephens, Matthew J Matasar

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.
Erel Joffe, Manik Uppal, Serena Zheng, Kurt S Bantilan, Connie Batlevi, Matthew Matasar

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives of Lymphoma Survivors and Oncology Care Providers on Survivorship Care: A Qualitative Study.
Jeanne M Ferrante, Myneka Macenat, Jenna Howard, Nimi Patel, Jaanvi Mahesh, Matthew Matasar

JCO Oncol Pract· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium.
Megan Melody, Natalie S Grover, Stephanie Franco, Jason T Romancik, Matthew J Cortese, Matthew J Matasar

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.
Niloufer Khan, Parastoo B Dahi, Farhad Khimani, Andrei R Shustov, Mazyar Shadman, Matthew J Matasar

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.
Cecelia R Miller, Ying Huang, John N Allan, Seema A Bhat, David Bond, Matthew Matasar

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era.
Giulio Cassanello, Esther Drill, Annie Qiu, Mark D Ewalt, Paul Hamlin, Matthew J Matasar

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study.
Frederique St-Pierre, Subodh Bhatta, Peter G Doukas, Madeline Jenkin, Kaitlin Annunzio, Matthew J Matasar

Blood Cancer J· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
Max S Topp, Matthew Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, Stephen J Schuster, Sarit E Assouline

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
Elise A Chong, Elicia Penuel, Ellen B Napier, Rachel K Lundberg, Lihua E Budde, Matthew J Matasar

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
Adam S Kittai, Ying Huang, Sarah Miller, John N Allan, Seema A Bhat, Matthew Matasar

Blood Cancer J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin, Anita Kumar, Matthew Matasar

Leuk Lymphoma· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas.
Paola Ghione, Kurt S Bantilan, Erel Joffe, M Lia Palomba, Ariela Noy, Matthew Matasar

Blood Neoplasia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.
Pier Luigi Zinzani, Huaqing Wang, Jifeng Feng, Tae Min Kim, Rong Tao, Matthew Matasar

Blood Adv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron, Matthew J Matasar

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivorship preparedness and activation among survivors of lymphoma.
Sharon L Manne, Shawna V Hudson, Dena O'Malley, Katie A Devine, Matthew Matasar

J Cancer Surviv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Matthew J Matasar

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
Matthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, Eric Zuk, Danilo Di Maio

J Med Econ· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu, Matthew Matasar

Pharmacoeconomics· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis